Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva CEO Offers Small Insights Into Big Priorities As Run Up to Dec. 11

This article was originally published in The Pink Sheet Daily

Executive Summary

Teva CEO Jeremy Levin provided additional glimpses of the company’s new strategy on a Q3 earnings call in advance of an investor meeting on Dec. 11, where he and Teva management will reveal their full agenda. Levin again put the emphasis on “focus” and “discipline” over “pure growth,” confirmed the company’s ‘confidence in the MS drug laquinimod, and highlighted several senior management appointments that reflect Teva’s new priorities.

You may also be interested in...

Deals In Korea Heat Up As Handok Confirms Talks With Teva; Ildong Inks Deal With TG Therapeutics

In a flurry of recent activity with Korean pharmas, Handok confirms it is in acquisition talks with Teva, and Ildong inks licensing deal with TG Therapeutics.

Teva Rumored To Be In M&A Talks With Mid-sized Korean Pharma

Predictions of heightened M&A activity among smaller South Korean generic drug firms gained firmer ground this week after an offhand comment by a government official pointed to interest by Teva in a mid-tier firm.

Genzyme Prices MS Drug Aubagio At Discount To Established Therapies

FDA approved Aubagio for patients with relapsing forms of multiple sclerosis on Sept. 12. Sponsor Genzyme, owned by Sanofi, announced an annual price of $45,000 for the drug, below the only other oral therapy for MS, Novartis’ Gilenya.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts